Daily filing brief

Sammaan Capital’s USD 1 billion IHC Investment, Vodafone Idea Q1 Results and More: 10 Important BSE and NSE Announcements for 18 August 2026

By Daily BrieferPublished Updated

Sammaan Capital’s IHC investment and Vodafone Idea’s Q1 FY27 performance lead the corporate announcements for 18 August 2026. The 10-item brief also covers Tata Motors’ Q1 FY27 results, pharmaceutical updates and fundraising disclosures for investors and shareholders.

  1. Sammaan Capital Ltd

    Sammaan Capital announces new promoter IHC with USD 1 billion investment and board control

    Press Release / Media Release

    Promoter change and investment

    • New promoter is IHC, now controls the board.
    • IHC commits to invest USD 1 billion in Sammaan Capital.

    Regulatory status and PIL update

    • Sammaan Capital not an accused; Supreme Court asks CBI to examine FIR.
    • CBI investigations focus on Yes Bank and IHFL promoters; SCL not under investigation.
    • Regulators including MCA, NHB, SEBI, RBI, EOW found no wrongdoing.
    • SCL ceased promoter relations in 2023; no connection since.
    View source

  2. Vodafone Idea Ltd

    Vodafone Idea Q1 FY27: Revenue up 6% YoY to Rs 11,689 crore; cash EBITDA Rs 2,475 crore; capex plan Rs 45,000 crore over 3 years

    Earnings Call Transcript

    Financial Performance

    • Revenue for Q1 FY27: Rs 11,689 crore, up 6.0% YoY.
    • Cash EBITDA: Rs 2,475 crore, up 13.5% YoY.
    • EBITDA: Rs 5,034 crore; margin 43.1% (vs 41.8% prior).
    • EBITDA margin expanded by 120 bps to 43.1%.
    • Capex in quarter: Rs 1,930 crore.
    • Exceptional item: Rs 1,816 crore benefit from CLAM fair value adjustment.
    • Net subscriber addition turned positive for the first time since merger.
    • Total subscribers: 193.1 million; 4G/5G subscribers: 130.1 million.
    • ARPU: Rs 195; YoY +10.2%; QoQ +2.6%.

    Operations and Enterprise Update

    • 4G coverage expanded to 87.0% pan-India.
    • 5G live in 200+ cities across 17 circles; 15,600 5G sites live.
    • 5G sites deployed: ~16,000; 4G towers deployed: 32,000 in 2 years.
    • Nearly 15,500 new broadband towers added in 12 months.
    • Average data per 4G/5G subscriber: 21.7 GB.
    • Total data usage: 88.4 PB/day, up from 69.1 PB/day YoY.
    • Churn reduced by 0.24 percentage points YoY.
    • Enterprise updates: MSME ReadyForNext 5.0; MoU with APMSMEDC for 100,000+ MSMEs.
    • Spotify postpaid collaboration; Vi Edu+ with PhysicsWallah; Vi Instadata launched.
    • Roaming: Choose Your Own Plan available in 59 countries.
    • Meta silent verification with safe authentication; SPARC AI upgrade.

    Balance Sheet and Liquidity

    • Bank debt: Rs 211 crore as of 30 June 2026 (vs Rs 1,926 crore 30 Jun 2025).
    • Free cash and bank balance: Rs 6,558 crore as of 30 June 2026.
    • Net debt: Rs 3,489 crore as of the quarter.
    • Warrant proceeds received: Rs 1,183 crore (part of funding).
    • First tranche funding: Rs 6,400 crore; mix of debt and non-fund facilities.
    • Funding landscape: ECB and Indian private banks; PSU banks engagement ongoing.

    Capex and Projects

    • Capex plan: Rs 45,000 crore over the next 3 years.
    • Capex orders placed to date: Rs 9,000 crore; Q1FY27 capex deployed: Rs 1,930 crore.
    • Capex deployment pace: ~3,500 sites per month going forward.
    • Network vendors: orders with Ericsson, Nokia, Samsung, etc.
    • 4G rollout target: 55,000–57,000 sites; 5G target: 86,000–90,000 sites.
    • 5G rollout may extend into Year 3 due to fiber requirements.
    • Enterprise milestone: APMSMEDC MoU to empower 100,000 MSMEs.

    Guidance and Outlook

    • 3-year targets: sustained net addition, double-digit revenue growth, 3x cash EBITDA.
    • Financial architecture in place to support capex and road map.

    Q&A Highlights

    • Subscriber transition: postpaid additions positive; churn improving; M2M stable.
    • ARPU drivers: 2G→4G/5G upgrades and NonStop Hero impact.
    • ARPU level: current mix with 66% smartphone (4G/5G); 34% 2G.
    • Capex pace: 3,500 sites per month; 4G rollout to complete in 18 months.
    • Debt strategy: debt-raising path continues; promoter support reiterated.
    View source

  3. Tata Motors Ltd

    Tata Motors Q1 FY27: Standalone revenue rises 23% with broad-volume growth; Indonesia orders and EV momentum; FCF turns positive

    Earnings Call Transcript

    Financial Performance

    • Standalone revenue ₹19,300 crore, up 23% YoY.
    • Standalone EBITDA ₹2,300 crore; margin 11.7%.
    • Standalone EBIT margin 9.4%; down 20 bps.
    • Standalone PBT before exceptional items ₹2,100 crore; up 26%.
    • Standalone Free Cash Flow ₹1,100 crore; swing from -₹1,800.
    • Standalone net cash ₹7,100 crore as of Jun 30; dividend ₹1,473 crore paid.
    • Consolidated revenue ₹20,700 crore; up 19%.
    • Consolidated EBITDA ₹2,300 crore; margin 10.9%.

    Volumes & Mix

    • Q1 standalone volumes 108,700 units; up 26% YoY.
    • HCV 26.4K; ILMCV 17.1K; SCV pickup 38.3K; CV Passenger 18.7K; Exports 8.1K.
    • VAHAN share up 100 bps sequential; heavy CV share 56.3%.

    Cash Flow & Balance Sheet

    • FleetEdge installed base >1 million; utilization improving MoM.
    • Free cash flow (Q1) ₹1,114 crore; YoY swing from -₹1,796.
    • Consolidated net cash ₹13,500 crore as of Jun 30; strong liquidity.
    • Capex ₹554 crore in Q1; ~₹600 crore prior year; 2.7% of revenue in Q1.
    • Working capital consumed ₹232 crore in Q1, vs ₹3,474 crore prior year.

    EVs, Products & International

    • EV volumes grew almost threefold YoY; Intra EV orders rising.
    • SCV EV penetration double-digit in May–June; 3,200+ Intra EV retails in Q1.
    • 850 electric bus orders; Smart City EV uptime >59 crore km.
    • Intra EV capacity not a challenge; cell lead times bottleneck; debottlenecking planned.
    • Indonesia deliveries ~2,000 in Q1; ramping up; 35% YoY growth despite limited Middle East shipments.

    Outlook & Guidance

    • Q2 expected to show healthy double-digit YoY growth.
    • Indonesia 70,000 orders to be supplied over FY27 and FY28.
    • July price hike of 2.5%; pass-through expected during the quarter.
    • Total investment spending in Q1 ₹515 crore; ~2.7% of revenue; within 2–4% guided.

    Q&A Highlights

    • Q2 double-digit YoY growth; demand remains robust post-monsoon.
    • Indonesia orders timeline clarified: 70k units over FY27–FY28.
    • EV pricing strategy: 2.5% July hike; pass-through anticipated.
    • EV financing improving; battery warranty offered; financiers confident.
    • Tamil Nadu demand improving post-election slowdown.
    • Market-share gains expected to continue.
    View source

  4. Zydus Lifesciences Ltd

    Zydus Lifesciences Q1 FY27: ₹80.2 bn revenue, 24.1% EBITDA margin; US/Intl growth fuels momentum

    Earnings Call Transcript

    Financial Performance

    • Consolidated revenues ₹80.2 billion, up 22% YoY.
    • EBITDA margin 24.1%; EBITDA ₹19.3 billion.
    • Net profit ₹9.4 billion.
    • Net debt to EBITDA 0.7x as on 30 June 2026.

    Segment Highlights

    • India branded formulations +20% YoY; broad-based growth.
    • Chronic/sub-chronic portfolio 54.2% per AWACS MAT Jun 2026.
    • International formulations ₹9.7 billion, up 34% YoY.
    • North America ₹31 billion revenue; QoQ +5%; 5 ANDAs filed; 9 approvals (incl 4 tentative); 11 launches.
    • US branded share ~10% of US revenue; target >15% by year-end.
    • Canada: 2 ANDA approvals and 2 launches.
    • Consumer Wellness ₹14.3 billion, +67% YoY; intl +25% like-for-like; domestic +5%; skincare +35%; nutrition +16%; seasonal brands de-grew.
    • Medical devices ₹2.8 billion; focusing on focused therapies.

    Operations & Capex

    • Zydus Biotech Park injectable facility received EIR with VAI after GMP inspections.
    • JV with Sunshine Healthcare to establish Sri Lanka manufacturing facility.
    • FY27 capex guidance ₹1,500-₹1,600 crores.

    Innovation & Pipeline

    • US FDA priority review for Saroglitazar Magnesium (PBC).
    • India: Desidustat Phase III in sickle cell disease with ICMR collaboration.
    • Phase III ADC Biosimilar in India; MR vaccine dossier accepted by WHO.
    • 505(b)(2) portfolio: 19 in-house; 8 partnered; 4+ launched.
    • Rolvedon acquisition gives ~$15-20 million per quarter run-rate.

    Guidance & Outlook

    • FY27: strong double-digit revenue growth; India +300-500 bps vs market; US single-digit.
    • Branded portfolio expected to exceed two-thirds of revenue in the medium term.
    • EBITDA margin guided at 24%+ for FY27; long-term 28-30% by ~5 years.
    • Saro: FY28 launch; first 2 years investment; peak sales potential $200-300 million base; up to $400m+.

    Q&A Takeaways

    • Q1 guidance reaffirmed: strong double-digit revenue growth; India outpacing market by 300-500 bps.
    • Capex color: SEK/SEZ3 expansions, Moraiya/Goa/Baddi, new R&D center; one-off wellness land; CAR-T facility.
    • Rolvedon and Assertio: run-rate ~$15-20m per quarter; US pipeline expanding with 505(b)(2) assets.
    • Desidustat China progress: approved; NRDL reimbursement pending; 120 million CKD patients imply long-term upside.
    • Indocyanine Green launch with 180-day CGT exclusivity; US pipeline to support growth beyond 2026.
    View source

  5. PI Industries Ltd

    PI Industries Q1 FY27: Revenue ₹17,023 mn; EBITDA ₹3,693 mn; gross margin 57%; net cash ₹38 bn; capex ₹700–800 cr; strong biologicals growth and 90-molecule pipeline with imminent domestic Pioxaniliprole launch

    Earnings Call Transcript

    Financial Performance

    • Q1 FY27 revenue ₹17,023 million; gross margin 57%; EBITDA 22%.

    Operating Update

    • Domestic volume growth 12%; revenue growth 3% in Q1.
    • Biologicals grew 50% in quarter; R&D spend 3–4% of revenue.
    • Export environment challenging; currency and commodity volatility noted.

    Balance Sheet & Cash Flow

    • Net cash ₹38 billion; debt-free balance sheet.
    • Contract assets ~₹750 crore (June 2026).
    • Net working capital reduced by 19 days; cash release ₹300 crore.

    Capex & Projects

    • Capex guidance ₹700–₹800 crore for FY27; current quarter ₹250 crore.
    • Three focus areas: existing assets, new verticals, innovation-led approaches.
    • Commissioned flow-chemistry plant; enhanced process control and safety.

    Guidance & Outlook

    • FY27 revenue growth expected in the lower single digits; cycle-dependent.
    • ETR for FY27 expected around 24%.
    • FY27 to be better than FY26 driven by second-half export recovery.

    Q&A Highlights

    • Pipeline ~90 projects; majority in AgChem; 60% at advanced stage.
    • FY27 launches: 4–5 molecules; 2–3 in Electronics; 1–2 in Pharma/Health Sciences.
    • Pioxaniliprole domestic launch expected within the year; other geographies next year / year after.
    • New products contributed 16–18% in CSM; early-stage CRDMO visibility in Pharma.
    • Export volumes down ~8%, value down ~12%; currency benefits managed via pass-through.
    • Domestic volume growth offset by delayed sowing; growth trajectory intact.
    View source

  6. Natco Pharma Ltd

    Natco Pharma Q1 FY27: Revenue 794.4 cr, PAT 206.5 cr; Adcock stake up, Brazil growth 180%, guidance reaffirmed at 750 cr PAT; INR 2,000 cr fundraise planned

    Earnings Call Transcript

    Financial Performance

    • Consolidated revenue in Q1 FY27: INR 794.4 crores; Q1 FY26: INR 1,390.6 crores
    • Consolidated PAT: INR 206.5 crores; Q4 FY26 had one-time INR 115 crores tax benefit; normalized PAT up 34%
    • Adcock Ingram revenue: INR 1,582.8 crores; NATCO share of profit: INR 84.3 crores
    • NATCO held 35.75% in Adcock as of 30 Jun 2026; stake increased to 49% in July 2026
    • Domestic formulations revenue: INR 136 crores; Brazil revenue: INR 178 crores (growth 180%)
    • Canada sales: around INR 56 crores; Export formulations: INR 477 crores
    • Crop Health Sciences Q1 revenue: INR 40 crores; full-year Crop Health target: INR 750 crores
    • Total gross sales guidance for FY27: INR 3,300–3,400 crores
    • Net cash: around INR 1,400 crores; ~INR 3,000 crores spent on Adcock acquisitions over last year
    • Fundraise plan: INR 2,000 crores; options include QIP or rights; opportunities domestic and outside India

    Geography & Segments Update

    • Brazil revenue growth driven by flu-season performance; Q1 Brazil: INR 178 crores
    • Canada sales contributed to export formulations; geographical mix described; no exact rest-of-world split provided
    • Adcock Ingram contribution boosted earnings; strong quarter primarily from associate profits

    Cash, Balance Sheet & Capital Allocation

    • Net cash around INR 1,400 crores; earlier year-end cash commentary referenced ~INR 3,000 crores
    • Cash spent ~INR 3,000 crores on Adcock acquisitions in the last year
    • Plan to raise INR 2,000 crores for acquisitions and internal capex; uses include opportunities abroad and in India

    R&D, Pipeline & Regulatory

    • Current quarter R&D spend lower after prior year spike; run-rate not implied; milestones drive spend
    • Olaparib litigation: trial date in next few months; exclusivity maintained; dates not clarified
    • Semaglutide: Canada and Brazil dossiers not filed; status minus; India-focused updates planned later
    • Two U.S. launches planned in next financial year; confidentiality prevents naming molecules
    • ANDA target: 8–10 per year; FTF target: 2–3 per year; at least one or two FTF this year

    Guidance & Outlook

    • PAT guidance reaffirmed: around INR 750 crores; seasonal bump not to be annualized
    • India consolidated tax around 25.16%; India domestic around 27% due to CSR/disallowances
    • Crop Health guidance implies FY27 revenue around INR 750 crores; full-year gross sales INR 3,300–3,400 crores
    • Carfilzomib launch on track; plant upgrade to be completed by year-end; launch date not disclosed

    Q&A Highlights

    • Q: Export geography constant-currency growth; Brazil growth ~180%; Canada ~INR 56 crores
    • A: Seasonal cycles; Adcock profit share explains Q1 uplift; not a uniform run-rate across geographies
    • Q: Why sequentially lower international formulations in Q1; is pomalidomide a factor?
    • A: Product cycles vary; some products have seasonal tenders; overall annual guidance remains intact
    • Q: Crop Health loss; when is breakeven; next steps?
    • A: Q2 stronger; full-year revenue target around INR 750 crores; agro growth across Brazil/Canada/US
    • Q: Why raise INR 2,000 crores; how to use proceeds?
    • A: To fund acquisitions and internal capex; opportunities both inside and outside India
    View source

  7. Hindustan Construction Company Ltd

    Hindustan Construction Company authorised to raise up to ₹800 crore via equity issuances (QIP, rights, preferential)

    Issue of Securities

    Fundraising authorization

    • Members authorised the Board to raise funds up to ₹800 crore via equity shares or equity-linked securities.
    • Issuances may be via QIP, preferential allotment, rights issue, or combinations.
    • Aggregate size up to ₹800 crore.
    • Type of securities: Equity shares or other equity-linked securities.
    • Board/Committee to decide the specific issuance type.
    • Issuances subject to applicable regulatory/statutory approvals.
    • No pricing details disclosed.
    View source

  8. Ashoka Buildcon Ltd

    Ashoka Buildcon Q1 FY27: Standalone revenue flat; consolidated down; guidance lowered to 10-15% growth; monetization progress underway

    Earnings Call Transcript

    Financial Performance

    • Standalone total income: INR 1,320 crores; flat vs Q1 FY26 (INR 1,339 crores).
    • Standalone EBITDA: INR 126 crores; margin 9.5%.
    • Standalone PAT: INR 31.5 crores; up 3% YoY.
    • Consolidated total income: INR 1,534 crores; down 21% YoY from INR 1,937 crores.
    • Consolidated EBITDA: INR 292 crores; margin 19.0%; down 55% YoY.
    • Consolidated PAT: INR 127 crores in Q1 FY27.
    • BOT toll Jaora-Nayagaon: INR 75 crores; up 8% YoY.

    Order Book and Segments

    • Order book as of 30 Jun: INR 15,251 crores; post-June INR 450 crores not yet included.
    • Road+Rail order book: INR 9,648 crores (63.3%).
    • HAM road orders: approx INR 1,500 crores.
    • EPC order book: approx INR 6,780 crores.
    • Railway: INR 1,346 crores; Power T&D: INR 5,066 crores (33.2%).
    • Building EPC: INR 536 crores (3.5%).
    • International wins: Guyana Versailles-Parika Highway INR 328 crores.
    • Gems & Jewellery Park, Raipur PPP: premium INR 112.4 crores; Ashoka 51% stake.
    • Dilution: Ashoka Purestudy Technologies from 59% to 39.33%.

    Monetization and Debt

    • Monetization: 4 assets by Sept-end; 2 assets by Dec/Mar quarter-end.
    • Total monetization value INR 1,150 crores (rounded); 4 assets ~INR 700 crores realized by Sept.
    • Cash receipts: holdbacks ~INR 30-40 crores; receipts underway.
    • Post-monetization third-party debt ~INR 500-600 crores; consolidated ~INR 1,100-1,200 crores.
    • Standalone debt ~INR 2,100 crores; Q1 interest cost ~INR 60 crores; year-end ~INR 50 crores.
    • Equity in Jaora-Nayagaon & Chennai ORR: Jaora initial INR 278 crores; effective Chennai ORR cost ~INR 300 crores for 100% stake.

    Capex & Guidance

    • Q1 capex: INR 25 crores; INR 7 crores international; balance domestic.
    • FY27 capex target: INR 125 crores.
    • HAM: Bowaichandi AD (appointed date) expected October first week; year-end progress ~15%.
    • FY28 margins expected 10.5-11%; ramp-up yields better margins.
    • Overseas revenue: Q1 overseas ~INR 145.1 crores; ~80% from Guyana.

    Q&A Highlights

    • Bid pipeline: NHAI/MoRTH ~INR 1 lakh crores; states ~INR 25k crores; railways ~INR 50k crores; other EPC.
    • Bid pipeline yet-to-open: around INR 8,000 crores.
    • Guidance: revenue growth 10-15%; order inflow 6,000-8,000 crores; Q1 inflow ~800.
    • HAM investments: INR 179 crores in 26-27; INR 72 crores in 27-28; INR 72 crores in 28-29.
    • Asset monetization: 4 assets by Sept; 2 by Dec; total ~INR 1,100-1,150 crores; holdbacks ~INR 30-40 crores.
    • Debt trajectory: standalone ~INR 2,100 crores; post-monetization third-party ~INR 500-600 crores; consolidated ~INR 1,100-1,200 crores.
    • Geography: Q1 overseas INR ~INR 145.1 crores; ~80% from Guyana.
    View source

  9. Balrampur Chini Mills Ltd

    Balrampur Chini Mills Q1 FY27: Sugar and Distillery revenues rise; PLA project on track with significant capex

    Earnings Call Transcript

    Financial Performance

    • Q1 FY27 started on a stable note; revenues up across Sugar and Distillery.
    • Higher sugar realizations supported profitability despite higher cane costs.
    • First quarter off-season; profitability impacted by inventory carrying costs.
    • Sugar inventory as of June 30: 45.67 lakh quintals.
    • Average carrying cost: INR 37.19 per kg.
    • 80,000-tonne PLA plant on track; INR 2,180 crore spent by end of July.
    • Product development, trials, and market engagement progressing.

    Operations and Projects

    • Sugarcane crushing and production increased due to better cane availability.
    • PLA project progress: construction, civil work, equipment arrivals.
    • Pricing and product development progress in PLA trials.
    • Integrated business model supports value from cane and diversification.

    PLA and Packaging Opportunity

    • Gutka/pan masala packaging shift towards PLA; trials positive; 2–3 months.
    • PLA packaging could absorb a large opportunity; paper alternative exists but PLA viable.
    • PLA costs competitive; banned goods packaging also uses PLA.
    • Large, unquantified PLA opportunity; reliable data unavailable.
    • PLA packaging cost-competitive versus aluminium; trials ongoing.

    Q&A Highlights

    • Distillery margins resilient; transfer pricing rose; quarter-specific due to feedstock mix.
    • Commissioning: lactic plant in Oct; PLA plant in Dec.
    • Expect 40% average PLA capacity utilization Jan–Mar; target higher.
    • Sugar price trajectory up; potential cane price hike; mixed near-term effects.
    • International sugar view: Brazil around 40 million tonnes; EU deficit 1–2 million.
    • Cane sowing good; yields look better; regionally variable.
    • El Niño narrative not as alarming; markets price risk, not alarm.
    • Mid-to-long-term PLA outlook; 100% utilization possible with time.
    • Internally all evidence gathered looks positive on marketing and production fronts.
    View source

  10. Oxford Industries Ltd

    Oxford Industries to hold 45th AGM via VC on Sep 11, 2026 with 99% capital reduction plan

    AGM

    AGM Details

    • 45th AGM on 11 September 2026 at 3:00 PM via VC/OAVM
    • Book closure from 5 to 11 September 2026 (inclusive)
    • Remote e-voting from 8 September 2026, 09:00 to 10 September 2026, 17:00
    • EV voting cut-off date: 4 September 2026

    Resolutions Put to Vote

    • Ordinary: adoption of audited financial statements for year ended 31 March 2026
    • Ordinary: appointment of Lipika & Associates as Statutory Auditors for five years
    • Special: regularize Katta Devi as Director (Non-Executive Non-Independent)
    • Special: adoption of MOA under Companies Act 2013
    • Special: adoption of AOA under Companies Act 2013
    • Special: enlargement of MOA main object to include healthcare activities
    • Special: shift of registered office from Maharashtra to Odisha
    • Special: reduction of capital by writing off losses (99% reduction)
    • Special: implementation of capital reduction, including issue of new shares
    • Open offer: promoter-acquirer for 26% stake at ₹5 per share

    Auditor & Directors

    • Previous statutory auditor resigned June 19, 2026; Lipika & Associates appointed for 5 years
    • Secretarial auditor Suprabhat & Co. appointed for 3 years
    • MD/Executive: Saroj Kumar Choudhury appointed MD/ED on 10 July 2025
    • Independent directors: Iranee Tripathy, Aakansha Vaid, Nitin Arvind Oza appointed in 2025
    • Director regularization: Katta Devi appointed 6 Mar 2026; later WTD resignation noted

    Dividend

    • Dividend for the year not proposed

    Director & KMP Changes

    • Resignations: Quaid Mohammed Hararwala (Aug 12, 2025); Misbah Huned Hararwala (Oct 18, 2025); Mazher Nuruddin Laila (Feb 12, 2026)
    • Poonam Sharma appointed Company Secretary & Compliance Officer (Dec 26, 2025)
    • Mazher Laila resigned as CFO (Feb 12, 2026); Saroj Choudhury appointed CFO (Jul 17, 2026)

    Material Related Party Transactions

    • Carbine Enterprises Pvt. Ltd.: borrowings (0.60 L) and repayments (120.60 L)
    • Blossom Texfab LLP: finished fabric purchases ₹219.11 L (2025-26) / ₹263.71 L (2024-25)
    • Zoho Enterprises LLP: acquisition of unlisted equity shares ₹32.94 L
    • Ali Laila: rent payable ₹0.06 L
    • MUFG Intime India Pvt Ltd: year-end balance disclosed

    Other Material Approvals / Open Offer

    • Open Offer: acquirer to purchase 26% stake at ₹5 per share; status noted
    • Scheme subject to NCLT sanction and ROC filings; BSE intimation required
    • Designation of stock exchange for scheme: BSE
    View source